Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
Amgen today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical study for LUMAKRAS TM in previously treated patients with non-small cell lung cancer during the 2021 American Society of Clinical Oncology Annual Meeting. These data were also simultaneously published in the New England Journal of Medicine . The publication includes mature overall .
Tislelizumab demonstrated a 30% reduction in the risk of death and extended median overall survival by 2.3 months compared to chemotherapy in advanced or metastatic esophageal squamous cell carcinoma after
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
Message :
Required fields
Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapy
First patient who failed Keytruda and chemotherapy has been dosed with plinabulin, Keytruda and radiation combination in non-small cell lung cancer (NSCLC)
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the first patient had been dosed in the Phase 1b/2 investigator-initiated trial, studying the safety and tolerability of plinabulin, in triple combination therapy with both PD-1/PD-L1 antibody (mAb) and radiation therapy (RT). This triple combination is actively recruiting at The University of Texas MD Anderson Cancer Center, with Dr. Vivek Subbiah as principal investigator, in seven metastatic or locally advanced cancers, whi